Conflicting meal recommendations for oral oncology drugs: pose risks to patient care?

Impact of dosage timing on the bioavailability of oral anticancer medications: Is pre-prandial dosing equivalent to post-prandial dosing

(2018) Guo Yu et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

(2016) David Planchard et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor

(2016) Ahmed Hamed Salem et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

(2016) Neeraj Gupta et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The role of a meal on gastrointestinal toxicity and maximum tolerated dose

(2016) Guo Yu et al.   LANCET ONCOLOGY

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

(2016) Stephan Stilgenbauer et al.   LANCET ONCOLOGY

Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors

(2015) Christian Rolfo et al.   ADVANCES IN THERAPY

Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects

(2015) Yvonne Y. Lau et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Similarities and Differences in Gastrointestinal Physiology Between Neonates and Adults: a Physiologically Based Pharmacokinetic Modeling Perspective

(2014) Guo Yu et al.   AAPS Journal

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

(2014) Matthias Freiwald et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers

(2014) Robert Shumaker et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye

(2014) Guo Yu et al.   LANCET ONCOLOGY

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use

(2013) Silvy da Rocha Dias et al.   EUROPEAN JOURNAL OF CANCER

Effects of food on the pharmacokinetics of ponatinib in healthy subjects

(2013) N. I. Narasimhan et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors

(2013) Daniele Ouellet et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Absolute Bioavailability and Effect of Formulation Change, Food, or Elevated pH with Rabeprazole on Cobimetinib Absorption in Healthy Subjects

(2013) Luna Musib et al.   MOLECULAR PHARMACEUTICS

The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

(2011) Geoffrey I. Shapiro et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

(2009) C Tanaka et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients

(2009) Kevin M. Koch et al.   JOURNAL OF CLINICAL ONCOLOGY